Sanara MedTech (NASDAQ:SMTI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Sanara MedTech (NASDAQ:SMTI) from a hold rating to a buy rating in a research report released on Saturday.

SMTI has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of Sanara MedTech in a report on Monday, January 26th. Zacks Research downgraded shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $36.00.

Sanara MedTech Stock Performance

NASDAQ:SMTI opened at $17.29 on Friday. Sanara MedTech has a twelve month low of $16.05 and a twelve month high of $35.95. The company has a quick ratio of 1.59, a current ratio of 1.80 and a debt-to-equity ratio of 7.75. The stock’s 50-day simple moving average is $19.88 and its 200 day simple moving average is $24.18. The firm has a market capitalization of $158.55 million, a PE ratio of -4.09 and a beta of 1.04.

Sanara MedTech (NASDAQ:SMTI) last issued its earnings results on Tuesday, March 24th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.07). The business had revenue of $27.55 million for the quarter, compared to analyst estimates of $27.90 million. Sanara MedTech had a negative return on equity of 20.73% and a negative net margin of 36.42%. On average, analysts anticipate that Sanara MedTech will post -1.1 EPS for the current fiscal year.

Institutional Trading of Sanara MedTech

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rockefeller Capital Management L.P. acquired a new position in shares of Sanara MedTech in the fourth quarter valued at approximately $299,000. NewEdge Advisors LLC acquired a new stake in Sanara MedTech during the 4th quarter worth approximately $243,000. Price T Rowe Associates Inc. MD boosted its position in Sanara MedTech by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,698 shares of the company’s stock worth $204,000 after buying an additional 2,100 shares during the period. Royal Bank of Canada grew its holdings in Sanara MedTech by 127.3% during the 4th quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock worth $2,747,000 after acquiring an additional 65,887 shares during the last quarter. Finally, Squarepoint Ops LLC grew its holdings in Sanara MedTech by 56.0% during the 4th quarter. Squarepoint Ops LLC now owns 48,953 shares of the company’s stock worth $1,143,000 after acquiring an additional 17,570 shares during the last quarter. 8.10% of the stock is currently owned by institutional investors.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.